88 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
1
Development of synthetic lethality anticancer therapeutics.
The University of Texas M.D. Anderson Cancer Center
13
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors.
Novartis Institutes For Biomedical Research
14
Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors.
Novartis Institutes For Biomedical Research
99
1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.
Newcastle University
16
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
Novartis Institutes For Biomedical Research
38
Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.
AstraZeneca
14
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
Cellzome
27
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
AstraZeneca
118
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
University of Oxford
51
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
Vertex Pharmaceuticals
1
Small molecule-based reversible reprogramming of cellular lifespan.
Korea Advanced Institute of Science and Technology
49
Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
Wyeth Research
1
The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
Kudos Pharmaceuticals
36
An update on small molecule compounds targeting synthetic lethality for cancer therapy.
Sichuan University
11
Progress of ATM inhibitors: Opportunities and challenges.
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
31
Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor.
Chinese Academy of Medical Sciences & Peking Union Medical College
25
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers.
The University of Texas MD Anderson Cancer Center
1
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Wyeth Research
1
Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.
The Scripps Research Institute
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
4
Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment.
China Pharmaceutical University
35
Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies.
Shanghai Institute of Materia Medica
30
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).
Repare Therapeutics, Inc.
21
Recent Advances on Small-Molecule Bromodomain-Containing Histone Acetyltransferase Inhibitors.
Sichuan University
36
Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual Screening.
Sichuan University
17
Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes.
Novartis Institutes for Biomedical Research
60
Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design.
Shenyang Pharmaceutical University
42
Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase.
China Pharmaceutical University
44
Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo.
Sichuan University
91
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Csir-Indian Institute of Integrative Medicine
56
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Hubei Polytechnic University
83
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Indian Institute of Technology (B.H.U.)
2
7-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
University Hospital Hradec Kralove
84
Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
Newcastle University
12
Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
University of Newcastle
30
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.
Bayer
32
Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.
Charles River
43
Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.
Chdi Management/Chdi Foundation
50
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
Bayer
46
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AstraZeneca
19
Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
Vertex Pharmaceuticals (Europe)
28
Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.
China Pharmaceutical University
34
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
AstraZeneca
24
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
Vertex Pharmaceuticals
15
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.
Vertex Pharmaceuticals
18
Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.
AstraZeneca
21
Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR).
Integral Biosciences
41
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
AstraZeneca
4
Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
Sunshine Lake Pharma
3
Triamterene or nolatrexed for use in the treatment of phenylketonuria
Som Innovation Biotech
3
AMIDO PYRIDO[3,4-B]INDOLE-1,4-DIONE COMPOUNDS FOR TREATMENT OF PORPHYRIAS
Portal Therapeutics
821
COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS
Sagimet Biosciences
3
Benzamide and active compound compositions and methods of use
Translational Drug Development
1
Diarylpyrazole compound, composition comprising same, and use thereof
Shenzhen Targetrx
32
Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity
Shionogi
14
Substituted benzimidazoles, their preparation and their use as pharmaceuticals
Epigenetix
32
Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection
Hoffmann-La Roche
25
Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists
University of California
13
Potent and Selective EphA4 Agonists for the Treatment of ALS.
Sanford Burnham Prebys Medical Discovery Institute
15
Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
Kissei Pharmaceutical
143
Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
Array Biopharma
9
Structural determinants of inhibitor selectivity in prokaryotic IMP dehydrogenases.
Brandeis University